A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines

Administration of PCSK9-specific monoclonal antibodies, as well as peptide-based PCSK9 vaccines, can lower plasma LDL cholesterol by blocking PCSK9. However, these treatments also cause an increase in plasma PCSK9 levels, presumably due to the formation of immune complexes. Here, we utilize a versat...

Descripción completa

Detalles Bibliográficos
Autores principales: Goksøyr, Louise, Skrzypczak, Magdalena, Sampson, Maureen, Nielsen, Morten A., Salanti, Ali, Theander, Thor G., Remaley, Alan T., De Jongh, Willem A., Sander, Adam F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864010/
https://www.ncbi.nlm.nih.gov/pubmed/36679847
http://dx.doi.org/10.3390/vaccines11010002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864010/
https://www.ncbi.nlm.nih.gov/pubmed/36679847
http://dx.doi.org/10.3390/vaccines11010002

Ejemplares similares